Breast Cancer Treatments
Thinking about breast cancer treatments is undoubtedly not the most enjoyable activity
one can engage in, but knowing your options can be a revealing and empowering experience. If
you have been diagnosed with breast cancer, it is very likely you will have one or more of these
experts in your treatment team: a breast surgeon or surgical oncologist, who is a doctor
specializing in surgery to topically treat breast cancer; a radiation oncologist, who specializes in
using radiation against breast cancer–also a topical treatment.
Some other experts, who focus more on systemic treatments, are a medical oncologist–a doctor who uses chemotherapy,
hormone treatment, immunotherapy, and other medicines to battle cancer and a plastic surgeon
who–as you may know–is there to reconstruct or repair parts of the body.
Local, or topical, treatments treat the tumor without affecting the rest of the body; surgery
and radiation are local treatments. Depending on the type of breast cancer, its stage, and your
overall health, you may need other types of treatment as well (before or after surgery, or both):
those are called systemic treatments because they reach cells almost anywhere in the body.
Systemic treatments can be given by mouth, put into the bloodstream, or injected in a muscle.
2022 has been a great year for breast cancer treatment, as the FDA approved a new drug
to treat HER2-Low Breast Cancer: trastuzumab deruxtecan (T-DXd). The approval came
through on August 5, 2022 and this therapy is meant to help patients who suffer from HER-2-
Low Breast Cancer that has spread to other parts of the body and cannot be surgically removed.
The clinical trial results for T-DXd were presented by medical oncologist Shanu Modi to this
year’s American Society of Clinical Oncology meeting. The clinical trial was led by Memorial
Sloan Kettering Cancer Center, and according to Dr. Modi, its results redefine how many
patients with metastatic cancer will be treated.
Targeted therapy works by identifying and attacking certain types of cancer cells, but it
doesn’t kill normal cells so its side effects are fewer than other treatments. However, until now
HER2 treatment has not been successful in treating cancer that is HER2-low. During the trial,
patients were given Enhertu (or T-DXd) which targets the protein HER2. The patients who
received Enhertu did noticeably better than the patients who received standard chemotherapy!
The new targeted drug held the cancer of the receivers in check nearly twice as long, and also
increased the survival rate by 35%.
This is wonderful news for breast cancer patients, and a great advancement in breast
cancer research and treatments! To consider if this is the right treatment for you, ask your
medical professional, and seek as much information as possible before you make a decision.